Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Gonzalez (IVER)
  NCT04391127		 RCTivermectinplaceboCOVID 19 hospitalizedsome concern
36/37 inconclusive
    Hashim A
          NCT04591600    		 RCTivermectinstandard of careCOVID 19 hospitalizedsome concern
    		70/70 inconclusive
    • inconclusive 52 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 mild to moderate meta-analysis

    I-TECH (Lim)
          NCT04920942    		 RCTivermectincontrolCOVID-19 mild to moderatesome concern
    		241/249 inconclusive
    • inconclusive 25 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
    Abd-Elsalam
          NCT04403555    		 RCTivermectincontrolCOVID-19 mild to moderatehigh
    		82/82 inconclusive
      Babalola RCTivermectinlopinavir/ritonavirCOVID-19 mild to moderatehigh
      		21/20 no results
        Bukhari
                  NCT04392713        		 RCTivermectinstandard of careCOVID-19 mild to moderatehigh
        		50/50 suggested
        • suggested 10.6-fold increase in viral clearance by day 7 but with a low degree of certainty due to high risk of bias
        Kirti
                  CTRI/2020/08/027225        		 RCTivermectinplaceboCOVID-19 mild to moderatesome concern
        		57/58 inconclusive
        • inconclusive 20 % decrease in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
        RIVET-COV (Mohan) (12mg and 24mg)
                  CTRI/2020/06/026001        		 RCTivermectinplaceboCOVID-19 mild to moderatehigh
        		104/52 inconclusive
        • inconclusive 10 % increase in viral clearance ,viral clearance by day 7 (PE) but with a low degree of certainty due to high risk of bias
        Ahmed RCTivermectinplaceboCOVID-19 mild to moderatehigh
        		48/24 suggested
        • suggested 3.1-fold increase in viral clearance (time to event analysis only),viral clearance by day 14 (PE) but with a low degree of certainty due to high risk of bias
        Paradoxically comparison of day 7 and 14 virological clearance between ivermectin doxycycline group vs placebo was not statistically significant (HR 2.3[0.6-9.0] and 1.7[0.8-4.0])
        Chaccour
                  NCT04390022        		 RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
        		12/12 inconclusive
        • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias
        Chachar
                  NCT04739410        		 RCTivermectinstandard of careCOVID-19 mild to moderatehigh
        		25/25 inconclusive
        • inconclusive 19 % increase in clinical improvement,clinical improvement (7-day) (PE) but with a low degree of certainty due to high risk of bias
        Krolewiecki
                  NCT004381884        		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
        		30/15 inconclusive
          NCT04523831 (Mahmud)
                      NCT04523831          		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
          		200/200 safety concern
          • suggested 89 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 93 % increase in clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 56 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
          • statistically significant 17.6-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
          Shahbaznejad
                      IRCT20111224008507N3          		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
          		35/38 inconclusive

            COVID-19 severe or critically meta-analysis

            Galan
                          RBR-8h7q82            		 RCTivermectinchloroquine and derivativesCOVID-19 severe or criticallysome concern
            		53/115 suggested
            • inconclusive 6 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
            • suggested 86 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
            Galan
                          RBR-8h7q82            		 RCTivermectinhydroxychloroquineCOVID-19 severe or criticallysome concern
            		53/115 suggested
            • inconclusive 6 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
            • suggested 86 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
            Okumuş
                          NCT04646109            		 RCTivermectincontrolCOVID-19 severe or criticallyhigh
            		30/30 inconclusive
              4 studies excluded by filtering options (0 RCT / 4 OBS)

              PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
              Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

               

              - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons